Report Detail
Global Postmenopausal Vaginal Atrophy Drugs Market Research Report 2019
- RnM3058644 |
- 04 August, 2020 |
- Global |
- 116 Pages |
- QYResearch |
- Pharma & Healthcare
Postmenopausal Vaginal Atrophy Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Postmenopausal Vaginal Atrophy Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Postmenopausal Vaginal Atrophy Drugs market is segmented into
Premarin
Vagifem
Estrace
Estring
Femring
Segment by Application, the Postmenopausal Vaginal Atrophy Drugs market is segmented into
Vaginal Gels
Creams
Tablets
Rings
Patches
Regional and Country-level Analysis
The Postmenopausal Vaginal Atrophy Drugs market is analysed and market size information is provided by regions (countries).
The key regions covered in the Postmenopausal Vaginal Atrophy Drugs market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Postmenopausal Vaginal Atrophy Drugs Market Share Analysis
Postmenopausal Vaginal Atrophy Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Postmenopausal Vaginal Atrophy Drugs business, the date to enter into the Postmenopausal Vaginal Atrophy Drugs market, Postmenopausal Vaginal Atrophy Drugs product introduction, recent developments, etc.
The major vendors covered:
Actavis plc
Bionovo, Inc.
Endoceutics, Inc.
Novo Nordisk A/S
Pfizer Inc.
Teva Pharmaceuticals Ltd.
Therapeutics MD, Inc.
Shionogi & Company
Allergan plc
Shionogi & Co. Ltd.
1 Study Coverage
- 1.1 Postmenopausal Vaginal Atrophy Drugs Product Introduction
- 1.2 Market Segments
- 1.3 Key Postmenopausal Vaginal Atrophy Drugs Manufacturers Covered: Ranking by Revenue
- 1.4 Market by Type
- 1.4.1 Global Postmenopausal Vaginal Atrophy Drugs Market Size Growth Rate by Type
- 1.4.2 Premarin
- 1.4.3 Vagifem
- 1.4.4 Estrace
- 1.4.5 Estring
- 1.4.6 Femring
- 1.5 Market by Application
- 1.5.1 Global Postmenopausal Vaginal Atrophy Drugs Market Size Growth Rate by Application
- 1.5.2 Vaginal Gels
- 1.5.3 Creams
- 1.5.4 Tablets
- 1.5.5 Rings
- 1.5.6 Patches
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Postmenopausal Vaginal Atrophy Drugs Market Size, Estimates and Forecasts
- 2.1.1 Global Postmenopausal Vaginal Atrophy Drugs Revenue 2015-2026
- 2.1.2 Global Postmenopausal Vaginal Atrophy Drugs Sales 2015-2026
- 2.2 Global Postmenopausal Vaginal Atrophy Drugs, Market Size by Producing Regions: 2015 VS 2020 VS 2026
- 2.2.1 Global Postmenopausal Vaginal Atrophy Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
- 2.2.2 Global Postmenopausal Vaginal Atrophy Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Postmenopausal Vaginal Atrophy Drugs Competitor Landscape by Players
- 3.1 Postmenopausal Vaginal Atrophy Drugs Sales by Manufacturers
- 3.1.1 Postmenopausal Vaginal Atrophy Drugs Sales by Manufacturers (2015-2020)
- 3.1.2 Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Manufacturers (2015-2020)
- 3.2 Postmenopausal Vaginal Atrophy Drugs Revenue by Manufacturers
- 3.2.1 Postmenopausal Vaginal Atrophy Drugs Revenue by Manufacturers (2015-2020)
- 3.2.2 Postmenopausal Vaginal Atrophy Drugs Revenue Share by Manufacturers (2015-2020)
- 3.2.3 Global Postmenopausal Vaginal Atrophy Drugs Market Concentration Ratio (CR5 and HHI) (2015-2020)
- 3.2.4 Global Top 10 and Top 5 Companies by Postmenopausal Vaginal Atrophy Drugs Revenue in 2019
- 3.2.5 Global Postmenopausal Vaginal Atrophy Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
- 3.3 Postmenopausal Vaginal Atrophy Drugs Price by Manufacturers
- 3.4 Postmenopausal Vaginal Atrophy Drugs Manufacturing Base Distribution, Product Types
- 3.4.1 Postmenopausal Vaginal Atrophy Drugs Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Postmenopausal Vaginal Atrophy Drugs Product Type
- 3.4.3 Date of International Manufacturers Enter into Postmenopausal Vaginal Atrophy Drugs Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
- 4.1 Global Postmenopausal Vaginal Atrophy Drugs Market Size by Type (2015-2020)
- 4.1.1 Global Postmenopausal Vaginal Atrophy Drugs Sales by Type (2015-2020)
- 4.1.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Type (2015-2020)
- 4.1.3 Postmenopausal Vaginal Atrophy Drugs Average Selling Price (ASP) by Type (2015-2026)
- 4.2 Global Postmenopausal Vaginal Atrophy Drugs Market Size Forecast by Type (2021-2026)
- 4.2.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Type (2021-2026)
- 4.2.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue Forecast by Type (2021-2026)
- 4.2.3 Postmenopausal Vaginal Atrophy Drugs Average Selling Price (ASP) Forecast by Type (2021-2026)
- 4.3 Global Postmenopausal Vaginal Atrophy Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
- 5.1 Global Postmenopausal Vaginal Atrophy Drugs Market Size by Application (2015-2020)
- 5.1.1 Global Postmenopausal Vaginal Atrophy Drugs Sales by Application (2015-2020)
- 5.1.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Application (2015-2020)
- 5.1.3 Postmenopausal Vaginal Atrophy Drugs Price by Application (2015-2020)
- 5.2 Postmenopausal Vaginal Atrophy Drugs Market Size Forecast by Application (2021-2026)
- 5.2.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Application (2021-2026)
- 5.2.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue Forecast by Application (2021-2026)
- 5.2.3 Global Postmenopausal Vaginal Atrophy Drugs Price Forecast by Application (2021-2026)
6 North America
- 6.1 North America Postmenopausal Vaginal Atrophy Drugs by Country
- 6.1.1 North America Postmenopausal Vaginal Atrophy Drugs Sales by Country
- 6.1.2 North America Postmenopausal Vaginal Atrophy Drugs Revenue by Country
- 6.1.3 U.S.
- 6.1.4 Canada
- 6.2 North America Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Type
- 6.3 North America Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Application
7 Europe
- 7.1 Europe Postmenopausal Vaginal Atrophy Drugs by Country
- 7.1.1 Europe Postmenopausal Vaginal Atrophy Drugs Sales by Country
- 7.1.2 Europe Postmenopausal Vaginal Atrophy Drugs Revenue by Country
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 U.K.
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Type
- 7.3 Europe Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Application
8 Asia Pacific
- 8.1 Asia Pacific Postmenopausal Vaginal Atrophy Drugs by Region
- 8.1.1 Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales by Region
- 8.1.2 Asia Pacific Postmenopausal Vaginal Atrophy Drugs Revenue by Region
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 South Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Taiwan
- 8.1.9 Indonesia
- 8.1.10 Thailand
- 8.1.11 Malaysia
- 8.1.12 Philippines
- 8.1.13 Vietnam
- 8.2 Asia Pacific Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Type
- 8.3 Asia Pacific Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Application
9 Latin America
- 9.1 Latin America Postmenopausal Vaginal Atrophy Drugs by Country
- 9.1.1 Latin America Postmenopausal Vaginal Atrophy Drugs Sales by Country
- 9.1.2 Latin America Postmenopausal Vaginal Atrophy Drugs Revenue by Country
- 9.1.3 Mexico
- 9.1.4 Brazil
- 9.1.5 Argentina
- 9.2 Central & South America Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Type
- 9.3 Central & South America Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Application
10 Middle East and Africa
- 10.1 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs by Country
- 10.1.1 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales by Country
- 10.1.2 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Revenue by Country
- 10.1.3 Turkey
- 10.1.4 Saudi Arabia
- 10.1.5 U.A.E
- 10.2 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Type
- 10.3 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Application
11 Company Profiles
- 11.1 Actavis plc
- 11.1.1 Actavis plc Corporation Information
- 11.1.2 Actavis plc Description and Business Overview
- 11.1.3 Actavis plc Sales, Revenue and Gross Margin (2015-2020)
- 11.1.4 Actavis plc Postmenopausal Vaginal Atrophy Drugs Products Offered
- 11.1.5 Actavis plc Related Developments
- 11.2 Bionovo, Inc.
- 11.2.1 Bionovo, Inc. Corporation Information
- 11.2.2 Bionovo, Inc. Description and Business Overview
- 11.2.3 Bionovo, Inc. Sales, Revenue and Gross Margin (2015-2020)
- 11.2.4 Bionovo, Inc. Postmenopausal Vaginal Atrophy Drugs Products Offered
- 11.2.5 Bionovo, Inc. Related Developments
- 11.3 Endoceutics, Inc.
- 11.3.1 Endoceutics, Inc. Corporation Information
- 11.3.2 Endoceutics, Inc. Description and Business Overview
- 11.3.3 Endoceutics, Inc. Sales, Revenue and Gross Margin (2015-2020)
- 11.3.4 Endoceutics, Inc. Postmenopausal Vaginal Atrophy Drugs Products Offered
- 11.3.5 Endoceutics, Inc. Related Developments
- 11.4 Novo Nordisk A/S
- 11.4.1 Novo Nordisk A/S Corporation Information
- 11.4.2 Novo Nordisk A/S Description and Business Overview
- 11.4.3 Novo Nordisk A/S Sales, Revenue and Gross Margin (2015-2020)
- 11.4.4 Novo Nordisk A/S Postmenopausal Vaginal Atrophy Drugs Products Offered
- 11.4.5 Novo Nordisk A/S Related Developments
- 11.5 Pfizer Inc.
- 11.5.1 Pfizer Inc. Corporation Information
- 11.5.2 Pfizer Inc. Description and Business Overview
- 11.5.3 Pfizer Inc. Sales, Revenue and Gross Margin (2015-2020)
- 11.5.4 Pfizer Inc. Postmenopausal Vaginal Atrophy Drugs Products Offered
- 11.5.5 Pfizer Inc. Related Developments
- 11.6 Teva Pharmaceuticals Ltd.
- 11.6.1 Teva Pharmaceuticals Ltd. Corporation Information
- 11.6.2 Teva Pharmaceuticals Ltd. Description and Business Overview
- 11.6.3 Teva Pharmaceuticals Ltd. Sales, Revenue and Gross Margin (2015-2020)
- 11.6.4 Teva Pharmaceuticals Ltd. Postmenopausal Vaginal Atrophy Drugs Products Offered
- 11.6.5 Teva Pharmaceuticals Ltd. Related Developments
- 11.7 Therapeutics MD, Inc.
- 11.7.1 Therapeutics MD, Inc. Corporation Information
- 11.7.2 Therapeutics MD, Inc. Description and Business Overview
- 11.7.3 Therapeutics MD, Inc. Sales, Revenue and Gross Margin (2015-2020)
- 11.7.4 Therapeutics MD, Inc. Postmenopausal Vaginal Atrophy Drugs Products Offered
- 11.7.5 Therapeutics MD, Inc. Related Developments
- 11.8 Shionogi & Company
- 11.8.1 Shionogi & Company Corporation Information
- 11.8.2 Shionogi & Company Description and Business Overview
- 11.8.3 Shionogi & Company Sales, Revenue and Gross Margin (2015-2020)
- 11.8.4 Shionogi & Company Postmenopausal Vaginal Atrophy Drugs Products Offered
- 11.8.5 Shionogi & Company Related Developments
- 11.9 Allergan plc
- 11.9.1 Allergan plc Corporation Information
- 11.9.2 Allergan plc Description and Business Overview
- 11.9.3 Allergan plc Sales, Revenue and Gross Margin (2015-2020)
- 11.9.4 Allergan plc Postmenopausal Vaginal Atrophy Drugs Products Offered
- 11.9.5 Allergan plc Related Developments
- 11.10 Shionogi & Co. Ltd.
- 11.10.1 Shionogi & Co. Ltd. Corporation Information
- 11.10.2 Shionogi & Co. Ltd. Description and Business Overview
- 11.10.3 Shionogi & Co. Ltd. Sales, Revenue and Gross Margin (2015-2020)
- 11.10.4 Shionogi & Co. Ltd. Postmenopausal Vaginal Atrophy Drugs Products Offered
- 11.10.5 Shionogi & Co. Ltd. Related Developments
- 11.1 Actavis plc
- 11.1.1 Actavis plc Corporation Information
- 11.1.2 Actavis plc Description and Business Overview
- 11.1.3 Actavis plc Sales, Revenue and Gross Margin (2015-2020)
- 11.1.4 Actavis plc Postmenopausal Vaginal Atrophy Drugs Products Offered
- 11.1.5 Actavis plc Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
- 12.1 Postmenopausal Vaginal Atrophy Drugs Market Estimates and Projections by Region
- 12.1.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Regions 2021-2026
- 12.1.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue Forecast by Regions 2021-2026
- 12.2 North America Postmenopausal Vaginal Atrophy Drugs Market Size Forecast (2021-2026)
- 12.2.1 North America: Postmenopausal Vaginal Atrophy Drugs Sales Forecast (2021-2026)
- 12.2.2 North America: Postmenopausal Vaginal Atrophy Drugs Revenue Forecast (2021-2026)
- 12.2.3 North America: Postmenopausal Vaginal Atrophy Drugs Market Size Forecast by Country (2021-2026)
- 12.3 Europe Postmenopausal Vaginal Atrophy Drugs Market Size Forecast (2021-2026)
- 12.3.1 Europe: Postmenopausal Vaginal Atrophy Drugs Sales Forecast (2021-2026)
- 12.3.2 Europe: Postmenopausal Vaginal Atrophy Drugs Revenue Forecast (2021-2026)
- 12.3.3 Europe: Postmenopausal Vaginal Atrophy Drugs Market Size Forecast by Country (2021-2026)
- 12.4 Asia Pacific Postmenopausal Vaginal Atrophy Drugs Market Size Forecast (2021-2026)
- 12.4.1 Asia Pacific: Postmenopausal Vaginal Atrophy Drugs Sales Forecast (2021-2026)
- 12.4.2 Asia Pacific: Postmenopausal Vaginal Atrophy Drugs Revenue Forecast (2021-2026)
- 12.4.3 Asia Pacific: Postmenopausal Vaginal Atrophy Drugs Market Size Forecast by Region (2021-2026)
- 12.5 Latin America Postmenopausal Vaginal Atrophy Drugs Market Size Forecast (2021-2026)
- 12.5.1 Latin America: Postmenopausal Vaginal Atrophy Drugs Sales Forecast (2021-2026)
- 12.5.2 Latin America: Postmenopausal Vaginal Atrophy Drugs Revenue Forecast (2021-2026)
- 12.5.3 Latin America: Postmenopausal Vaginal Atrophy Drugs Market Size Forecast by Country (2021-2026)
- 12.6 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Market Size Forecast (2021-2026)
- 12.6.1 Middle East and Africa: Postmenopausal Vaginal Atrophy Drugs Sales Forecast (2021-2026)
- 12.6.2 Middle East and Africa: Postmenopausal Vaginal Atrophy Drugs Revenue Forecast (2021-2026)
- 12.6.3 Middle East and Africa: Postmenopausal Vaginal Atrophy Drugs Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Porter's Five Forces Analysis
- 13.5 Primary Interviews with Key Postmenopausal Vaginal Atrophy Drugs Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Postmenopausal Vaginal Atrophy Drugs Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
Summary:
Get latest Market Research Reports on Postmenopausal Vaginal Atrophy Drugs. Industry analysis & Market Report on Postmenopausal Vaginal Atrophy Drugs is a syndicated market report, published as Global Postmenopausal Vaginal Atrophy Drugs Market Research Report 2019. It is complete Research Study and Industry Analysis of Postmenopausal Vaginal Atrophy Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
